A 58-year-old male with COPD and recent hospitalization presents with fever (38.9°C), productive cough with greenish sputum, and dyspnea for 3 days. Chest X-ray shows bilateral lower lobe infiltrates. Sputum culture grows a gram-negative rod that is oxidase-positive, produces a fruity odor, and grows on cetrimide agar. Blood cultures remain negative. Which of the following is the most appropriate initial empirical antibiotic regimen for this patient?

Explanation

## Identification of Organism **Key Point:** The combination of oxidase-positive, gram-negative rod with fruity (grape-like) odor and growth on cetrimide (selective for *Pseudomonas*) agar is pathognomonic for *Pseudomonas aeruginosa*. ## Clinical Context This patient has hospital-acquired pneumonia (HAP) in a COPD patient with recent hospitalization — a classic risk factor for *Pseudomonas* infection. The organism is an opportunistic pathogen in hospitalized, immunocompromised, or structurally compromised lung patients. ## Antibiotic Management **High-Yield:** *Pseudomonas aeruginosa* is intrinsically resistant to many beta-lactams and requires: - **Anti-pseudomonal beta-lactams** (piperacillin-tazobactam, ceftazidime, carbapenems) OR - **Fluoroquinolones** (ciprofloxacin, levofloxacin) with enhanced lung penetration - **Aminoglycosides** (gentamicin, tobramycin, amikacin) for synergy in severe infection **Clinical Pearl:** Piperacillin-tazobactam (a ureidopenicillin + beta-lactamase inhibitor) combined with a fluoroquinolone or aminoglycoside is the standard empirical choice for *Pseudomonas* respiratory infection in hospitalized patients. Dual therapy is preferred for severe infections to reduce resistance emergence. ## Why Option 1 Is Correct Piperacillin-tazobactam is an anti-pseudomonal beta-lactam with excellent lung penetration. Addition of ciprofloxacin (respiratory fluoroquinolone) or an aminoglycoside provides synergy and broad coverage. ### Comparison of Anti-Pseudomonal Options | Agent | Activity vs *P. aeruginosa* | Lung Penetration | Typical Use | |-------|---------------------------|-----------------|-------------| | Ceftriaxone | Poor (intrinsic resistance) | Moderate | *E. coli*, *Klebsiella* — NOT *Pseudomonas* | | Piperacillin-tazobactam | Excellent | Excellent | HAP/VAP with *Pseudomonas* — **gold standard** | | Ciprofloxacin | Good | Excellent | Monotherapy or adjunct in respiratory *Pseudomonas* | | Aminoglycosides | Good (synergy) | Moderate (needs IV) | Adjunct for severe infection | | Cephalexin | Poor (intrinsic resistance) | Poor | Community-acquired, not anti-pseudomonal | **Mnemonic:** **CAPNEU** — *Pseudomonas aeruginosa* is resistant to **C**ephalosporins (1st/2nd gen), **A**moxicillin, **P**enicillin G, and **N**itrofurantoin. Requires **E**xtended-spectrum agents (**U**reidopenicillins, cephalosporins 3rd/4th gen, carbapenems). ## Resistance Mechanisms *Pseudomonas aeruginosa* resists beta-lactams via: 1. Chromosomal AmpC beta-lactamase (inducible) 2. Efflux pumps (MexAB-OprM system) 3. Altered penicillin-binding proteins Thus, standard cephalosporins and aminopenicillins are ineffective. [cite:Harrison 21e Ch 157]